Welcome to our dedicated page for Vicarious Surgical SEC filings (Ticker: RBOT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Vicarious Surgical’s SEC paperwork often means decoding pages of robotics engineering details, FDA trial data, and prototype cost breakdowns. If you have ever searched for “Vicarious Surgical SEC filings explained simply” or wondered how executive stock sales line up with regulatory milestones, you know the challenge.
Stock Titan solves that complexity. Our AI instantly scans every new document from the company’s real-time EDGAR feed—whether it’s a Vicarious Surgical quarterly earnings report 10-Q filing or a sudden Vicarious Surgical 8-K material events explained alert—and delivers plain-language summaries, trend charts, and red-flag highlights. You will see cash-burn trends, R&D outlays, and single-port robotics development updates without wading through technical jargon.
Here is what investors monitor most—and how our platform helps:
- 10-K / Annual insight: Get the Vicarious Surgical annual report 10-K simplified so you can track FDA pathway progress and component sourcing risks.
- 10-Q / Quarterly performance: Compare revenue runway and prototype expenses with our Vicarious Surgical earnings report filing analysis.
- Form 4 insider alerts: Follow Vicarious Surgical insider trading Form 4 transactions and receive Vicarious Surgical Form 4 insider transactions real-time push notices.
- Proxy statement: Drill into Vicarious Surgical proxy statement executive compensation to see how bonuses hinge on FDA milestones.
Need deeper context? Try understanding Vicarious Surgical SEC documents with AI—our narrative commentary ties robotic-arm dexterity claims to actual spending, while clear call-outs show Vicarious Surgical executive stock transactions Form 4 right next to board meeting dates. From early-morning 8-K announcements to late-day amendment filings, every disclosure appears on this page within minutes, already distilled into the insights that matter.
Vicarious Surgical Inc. (NYSE: RBOT) filed an 8-K covering governance and compensation actions taken at its 27 June 2025 Annual Meeting.
Equity Incentive Plan: Shareholders approved an amendment to the 2021 Equity Incentive Plan that raises the share reserve by 311,046 Class A common shares. The same incremental amount is now available specifically for Incentive Stock Options. All other plan terms remain unchanged and the full amended text is included as Exhibit 10.1.
Director Compensation Policy: Effective the same date, the Board adopted a restated non-employee director compensation policy. Key features include:
- Creation of a new Product & Technology Committee with annual cash retainers of $14,250 for the chair and $5,500 for members.
- Updated annual cash retainers across all committees (e.g., Audit Committee member — $6,300; Board member base retainer — $40,000).
- Flexibility for the Compensation Committee to grant equity awards at values below stated guidelines.
- Initial equity awards to new directors valued at up to $301,800 and annual awards valued at up to $145,000, delivered as RSUs or options.
Annual Meeting Voting: Approximately 4.1 million shares (≈90 % of voting power) were present, constituting a quorum. All nine director nominees were re-elected with more than 97 % of votes cast "for" each nominee. The equity plan amendment passed with 14,678,240 votes "for" (≈99.6 %), 50,817 "against" and 3,907 abstentions. Broker non-votes totaled 1,788,342.
No other material transactions, earnings data or strategic changes were disclosed.
Vicarious Surgical Inc. (RBOT) – Form 4 insider transaction
The filing discloses that Adam David Sachs, the company’s Chief Executive Officer, Director and >10% shareholder, executed a single sale of Class A common stock on 06/23/2025. A total of 279 shares were sold at a weighted-average price of $7.7996 per share. The transaction was carried out specifically to satisfy tax-withholding obligations arising from the vesting of restricted stock units granted on 11/23/2021.
Following the disposition, Sachs’ direct beneficial ownership stands at 50,444 Class A shares. No derivative security activity was reported in Table II. The filing states that the price represents an average of multiple trades executed between $7.62 and $7.90; full trade-level detail is available to the SEC or shareholders upon request.
Key contextual points for investors:
- The sale represents less than 1% of Sachs’ reported holdings, indicating a de-minimis impact on his ownership stake.
- The transaction is classified under code “S” (open-market sale) but is explicitly tied to tax withholding and therefore does not necessarily signal a change in sentiment.
- No other transactions, option exercises, or new awards were reported in the filing period.
Overall, the Form 4 reflects a routine administrative sale rather than a strategic reduction, and it is unlikely to materially affect the company’s governance or shareholder structure.
Sammy Khalifa, Chief Technology Officer, Director, and 10% Owner of Vicarious Surgical (RBOT), reported a tax-related transaction on June 23, 2025. The insider sold 223 shares of Class A Common Stock at a weighted average price of $7.8145 per share (ranging from $7.62 to $7.885).
Key details of the transaction:
- The sale was specifically executed to cover tax withholding obligations related to the vesting of restricted stock units originally granted on November 23, 2021
- Following the transaction, Khalifa maintains direct ownership of 35,407 shares
- The transaction was reported through Form 4 filed on June 24, 2025
This insider transaction appears to be a routine tax-related sale rather than a discretionary trading decision, as it was triggered by RSU vesting obligations.
Form 144 Notice of Proposed Sale filed by Vicarious Surgical (NYSE: RBOT) on June 28, 2025, detailing insider stock transactions. An insider plans to sell 279 shares of Class A Common Stock through UBS Financial Services, with an aggregate market value of $2,226.42. The total outstanding shares are 5,277,994.
The securities were originally acquired through a Restricted Stock Lapse of 812 shares on June 20, 2025. The seller, Adam Sachs, has conducted two previous sales in the past 3 months:
- May 20, 2025: 817 shares for $5,961 gross proceeds
- June 3, 2025: 463 shares for $3,210 gross proceeds
The filing indicates the seller has no knowledge of undisclosed material adverse information regarding the company's operations. The planned sale is scheduled for approximately June 23, 2025.
Vicarious Surgical (NYSE: RBOT) insider filing reveals planned sale of 223 shares of Class A Common Stock with an aggregate market value of $1,779.54. The sale is scheduled for June 23, 2025, through UBS Financial Services.
The shares being sold were acquired on June 20, 2025, through a Restricted Stock Lapse of 694 shares. The seller, who has recent trading history, previously sold:
- 653 shares on May 20, 2025 (proceeds: $4,748)
- 239 shares on June 3, 2025 (proceeds: $1,641)
The filing indicates there are 5,277,994 shares outstanding. This Form 144 represents a notice of proposed sale of securities acquired through equity compensation, demonstrating ongoing insider transactions while maintaining regulatory compliance under Rule 144 of the Securities Act.
FAQ
What is the current stock price of Vicarious Surgical (RBOT)?
What is the market cap of Vicarious Surgical (RBOT)?
